Samantha Manfredini
Overview
Explore the profile of Samantha Manfredini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piombino C, Nasso C, Bettelli S, Manfredini S, Vitale M, Pipitone S, et al.
Cancer Med
. 2025 Feb;
14(4):e70472.
PMID: 39980141
Background: The therapeutic management of metastatic hormone-sensitive prostate cancer (mHSPC) is still based on clinical and pathological parameters due to the lack of biomarkers that may drive tailored treatment. Methods:...
2.
Canino F, Tornincasa A, Bettelli S, Manfredini S, Barbolini M, Moscetti L, et al.
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38473737
Over the last two decades, the use of Next-Generation Sequencing (NGS) in medical oncology has increased the likelihood of identifying druggable mutations that may be potentially susceptible to targeted treatments....
3.
Samarelli A, Tonelli R, Raineri G, Bruzzi G, Andrisani D, Gozzi F, et al.
Front Oncol
. 2024 Feb;
13:1275346.
PMID: 38322285
Introduction: Idiopathic pulmonary fibrosis (IPF) severely affects the lung leading to aberrant deposition of extracellular matrix and parenchymal stiffness with progressive functional derangement. The limited availability of fresh tissues represents...
4.
DOnofrio R, Caputo F, Prampolini F, Spallanzani A, Gelsomino F, Bettelli S, et al.
Tumori
. 2022 Sep;
109(4):387-393.
PMID: 36113407
Aim: To apply extended ctDNA-based RAS genotyping to clinical criteria for improving the selection of patients eligible for anti-EGFR-based rechallenge in a real-world setting. Methods: ctDNA testing was prospectively applied...
5.
Guaitoli G, Bertolini F, Bettelli S, Manfredini S, Maur M, Trudu L, et al.
Int J Mol Sci
. 2021 Dec;
22(23).
PMID: 34884672
rearrangements are reported in about 1-2% of non-squamous non-small-cell lung cancer (NSCLC). After efficacy of crizotinib was demonstrated, identification of translocations in advanced disease became fundamental to give patients the...
6.
Cesinaro A, Gallo G, Manfredini S, Maiorana A, Bettelli S
Histopathology
. 2021 Jul;
79(6):966-974.
PMID: 34231248
Aims: Spitzoid tumours have been shown to harbour exclusive kinase fusions. Few studies have analysed substantial numbers of ROS1-rearranged lesions. The aim of the present study was to investigate also...
7.
Omarini C, Bettelli S, Manfredini S, Barbolini M, Isca C, Cortesi G, et al.
Transl Oncol
. 2020 Jun;
13(9):100794.
PMID: 32485588
Introduction: In early-stage HER2 positive breast cancer (BC) patients, tumor response to neoadjuvant chemotherapy (NACT) predict survival outcomes. Patients achieving less than pathological complete response (pCR) have a worse prognosis,...
8.
Aramini B, Banchelli F, Bettelli S, Manfredini S, DAmico R, Masciale V, et al.
Oncotarget
. 2020 Feb;
11(5):550-559.
PMID: 32082488
In addition to the most common somatic lung cancer mutations (i. e., KRAS and EGFR mutations), other genes may harbor mutations that could be relevant for lung cancer. We defined...
9.
Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, et al.
J Cancer Res Clin Oncol
. 2019 Jan;
145(4):821-828.
PMID: 30603906
Purpose: Hormone receptors (HR) status in HER2 + breast cancer (BC) is a recognized stratification factor with relevant clinical implication. According to HR expression, HER2 + BC show different clinical...
10.
Omarini C, Filieri M, Bettelli S, Manfredini S, Kaleci S, Caprera C, et al.
Biomed Res Int
. 2018 Aug;
2018:3756981.
PMID: 30140695
Background: Everolimus has been shown to overcome endocrine resistance in hormone receptor positive advanced breast cancer patients. Predictive biomarkers of everolimus efficacy have been investigated in primary breast cancer tissue...